Home » Authors » Jim Shrine

Articles by Jim Shrine

Cytos, Novartis Enter Potential $500M Deal On Nicotine Vaccine

April 26, 2007

BioMarin Raises $324.9M Via Offering Of Convertible Notes

April 25, 2007

Halozyme Brings In $32.1M Via Private Deal With New River

April 25, 2007

Halozyme Brings In $32.1M Via Private Deal With New River

April 25, 2007

BioMarin Raises $324.9M Via Offering Of Convertible Notes

April 25, 2007

MedImmune Offer Comes In High: AstraZeneca To Pay $15.2 Billion

April 24, 2007

MedImmune Inc., which officially put itself up for sale less than two weeks ago, agreed Monday to be acquired by AstraZeneca plc for $15.2 billion. (BioWorld Today)

MedImmune Offer Comes In High: AstraZeneca To Pay $15.2 Billion

April 24, 2007

MedImmune Inc., which officially put itself up for sale less than two weeks ago, agreed Monday to be acquired by AstraZeneca plc for $15.2 billion. (BioWorld Today)

Altus Raises $88.5M Publicly To Fund Protein Therapeutics

April 20, 2007

Altus Raises $88.5M Publicly To Fund Protein Therapeutics

April 20, 2007

Cel-Sci Raises $15M, Plans To Move MultiKine Into Phase III

April 19, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...